Anixa Biosciences Inc (ANIX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ANIX currently has 33.2M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 3.81% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 09, 2026 |
10-Q filing | 33.2M shares outstanding |
33M | 0 |
| Sep 10, 2025 |
S-3 filing: ANIXA Biosciences, Inc. is filing an S-3 form to offer various securities, including common stock, preferred stock, purchase contracts, subscription rights, depositary shares, and debt securities, for total gross proceeds of up to $200,000,000. |
33M | 0 |
| May 28, 2025 |
10-Q filing | 32.2M shares outstanding |
32M | 0 |
| Mar 11, 2025 |
10-Q filing | 32.2M shares outstanding |
32M | 0 |
| Jan 10, 2025 |
10-K filing | 32.2M shares outstanding |
32M | 0 |
| Sep 06, 2024 |
10-Q filing | 32.2M shares outstanding |
32M | 0 |
| Jun 04, 2024 |
10-Q filing | 32.0M shares outstanding |
32M | 0 |
| Mar 12, 2024 |
10-Q filing | 31.9M shares outstanding |
32M | 0 |
| Jan 16, 2024 |
10-K filing | 31.7M shares outstanding |
32M | 0 |
| Sep 06, 2023 |
10-Q filing | 31.1M shares outstanding |
31M | 0 |
| Jun 14, 2023 |
10-Q filing | 31.0M shares outstanding |
31M | 0 |
| Mar 17, 2023 |
10-Q filing | 30.9M shares outstanding |
31M | 0 |
| Jan 04, 2023 |
10-K filing | 30.4M shares outstanding |
30M | 0 |
| Sep 09, 2022 |
10-Q filing | 30.7M shares outstanding |
31M | 0 |
| Sep 09, 2022 |
S-3 filing: Anixa Biosciences, Inc. is offering common stock, preferred stock, purchase contracts, warrants, subscription rights, depositary shares, and debt securities for total gross proceeds of up to $200,000,000. |
31M | 0 |
| Jun 10, 2022 |
10-Q filing | 30.2M shares outstanding |
30M | 0 |
| Mar 11, 2022 |
10-Q filing | 30.1M shares outstanding |
30M | 0 |
| Jan 04, 2022 |
10-K filing | 30.1M shares outstanding |
30M | 0 |
| Sep 01, 2021 |
10-Q filing | 29.9M shares outstanding |
30M | 0 |
| Jun 10, 2021 |
10-Q filing | 24.2M shares outstanding |
24M | 0 |
| Mar 24, 2021 |
8-K filing: Anixa Biosciences, Inc. entered into an amended and restated underwriting agreement with H.C. Wainwright & Co., LLC to issue and sell 4,285,715 shares of common stock at a public offering price of $5.25 per share, with an option for the underwriters to purchase an additional 642,857 shares. |
24M | 0 |
| Mar 11, 2021 |
10-Q filing | 24.2M shares outstanding |
24M | 0 |
| Jan 07, 2021 |
10-K filing | 24.2M shares outstanding |
24M | 0 |
| Sep 08, 2020 |
10-Q filing | 23.8M shares outstanding |
24M | 0 |
| Jun 09, 2020 |
10-Q filing | 23.0M shares outstanding |
23M | 0 |
| Mar 09, 2020 |
10-Q filing | 21.0M shares outstanding |
21M | 0 |
| Jan 09, 2020 |
10-K filing | 20.8M shares outstanding |
21M | 0 |